Abstract:Abstract Background Inflammatory bowel disease (IBD) includes two chronic idiopathic inflammatory diseases: ulcerative colitis (UC) and Crohn disease (CD). The diagnosis of IBD depends on clinical, endoscopic, histological, radiological and biochemical criteria, which may be invasive, time consuming and usually not accepted by patients with IBD. Antineutrophil cytoplasmic antibodies (ANCAs) is believed to be related to IBD. The aim of this study was to investigate these serological markers and the evidence for their use in the diagnosis and management of IBD in Taiwan. Methods We conducted a retrospective cohort study in adult IBD patients who had received the serum examinations using the medical records of China Medical University Hospital between 1 January 1980 and 31 October. 2023. Results A total of 301 IBD patients (194 with UC, 107 with CD) were included in this current study. A high proportion were male (IBD 70.41%; UC 65.63%, and CD 76.71%). The mean diagnostic age of these enrolled patients was 42.9 years. In our patients, the prevalence of positive anti-HCV Ab is 0.0% in UC patients and 0.96% in CD patients. However, the prevalence of positive HBsAg was 14.5% in UC patients and 9.4% in CD patients. The prevalence of pANCA was 21.2% in UC patients and 1.4% in CD patients, respectively. The prevalence of cANCA was 3.1% in UC patients and 0.0% in CD patients. This pattern of low sensitivity and high specificity for pANCA is also seen in UC patients in various cohort studies. The serum positivity of p-ANCA was significantly higher in UC patients (Figure 1). UC patients with positive p-ANCA were older than CD patients with positive p-ANCA (44.9 vs. 37.3 years). Furthermore, we found that the incidence of positive p-ANCA in UC patients with E1, E2, and E3 at diagnosis was 3.5%, 39.2%, and 57.1%, respectively (Table 1). The serum levels of ANCA-IgG were indeed higher in patients in the severe group than those in the moderate and mild groups. Conclusion Serological biomarkers have been demonstrated to be a series of rapid, non-invasive approaches for assessments of early diagnosis, disease activity and prognosis for IBD. ANCA may be helpful in the early diagnosis of UC and in differentiating it from CD. UC patients with positive ANCA have a higher rate of intestinal mucosal vasculitis than UC patients with negative ANCA. Furthermore, ANCA may also contributes to the pathogenesis of HBV-related systemic vasculitis. Therefore, the management of HBV-related vasculitis includes control the immune complex formation and reaction as well as antiviral agents to reduce the antigenic load resulting in reduction of inflammation. Moreover, effective biomarkers with high sensitivity and specificity need to be investigated in the future.

The prevalence and diagnostic value of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease in mainland China.

Clinical significance of serum anti-microbial antibodies test in inflammatory bowel disease

Clinical Significance of Perinuclear Antineutrophil Cytoplasmic Antibodies and Anti-Saccharomyces cerevisiae Antibodies in Inflammatory Bowel Disease

Study on Joint Detection of Serological Markers in the Diagnosis of Crohn's Disease

Anti-neutrophil cytoplasmic antibodies (ANCA) and inflammatory bowel diseases in Chinese

Clinical Significance Of Anti-Sacchromyces Cerevisiae Antibody In Crohn'S Disease: A Single-Center Study

P264 The utility of ANCA in Ulcerative Colitis and Crohn’s Disease: A Retrospective Cohort Study in Taiwan

Clinical significance of detecting anti-Saccharomyces cerevisiae antibody in Crohn′s disease

Enterogenous Microbiotic Markers in the Differential Diagnosis of Crohn’s Disease and Intestinal Tuberculosis

Detection of biomarkers and its clinical signiifcance in the inlfammatory bowel disease in Children

Clinical Presentation of Inflammatory Bowel Disease： a Hospital Based Retrospective Study of 379 Patients in Eastern China

ENDO 2020 Blue Ribbon Poster Presentation

IDDF2019-ABS-0186 Correlation Between Serological Biomarkers and Disease Activity in Patients with Inflammatory Bowel Disease

The value of serum antibodies in differentiating inflammatory bowel disease, predicting disease activity and disease course in the newly diagnosed patient

Elevated serum anti-<i> Saccharomyces</i><i> cerevisiae</i> antibody accompanied by gut mycobiota dysbiosis as a biomarker of diagnosis in patients with de novo Parkinson disease

Characterization of Clinical and Serologic Features of Crohnʼs Disease and Anti-TNFα Use in a Chinese Cohort

A New Model for the Discrimination Between Ulcerative Colitis and Crohn's Disease.

The clinic significance and positive rate of antineutrophil cytoplasmic antibodies in patients with ulcerative colitis

The Application Value of Serological Detection of ASCA and ANCA Serum Level in the Diagnosis and Treatment of Inflammatory Bowel Disease

Prevalence and Clinical Relevance of Anti-FcεRI Autoantibody in Crohn's Disease

Diagnostic Value of Antineutrophil Cytoplasmic Antibodies in Patients with Ulcerative Colitis: a Meta-Analysis